We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Coherent Hemodynamics Spectroscopy Used to Diagnose Brain Damage Resulting from Concussions, Strokes, and Dementia

By MedImaging International staff writers
Posted on 05 Jan 2015
Print article
Image: New optical diagnostic technology promises new ways to identify and monitor brain damage resulting from traumatic injury, stroke, or vascular dementia—in real time and without invasive procedures (Photo courtesy of Tufts University).
Image: New optical diagnostic technology promises new ways to identify and monitor brain damage resulting from traumatic injury, stroke, or vascular dementia—in real time and without invasive procedures (Photo courtesy of Tufts University).
New optical diagnostic technology has the potential to provide a new way to identify and monitor brain damage resulting from traumatic injury, stroke, or vascular dementia in real time and without invasive procedures.

Coherent hemodynamics spectroscopy (CHS), a new technology developed by Tufts University (Medford/Somerville, MA, USA) professor of biomedical engineering Sergio Fantini, measures blood flow, blood volume, and oxygen consumption in the brain. It uses noninvasive near infrared (NIR) light technology to scan brain tissue, and then applies mathematical algorithms to interpret that data. “CHS is based on measurements of brain hemodynamics that are interpreted according to unique algorithms that generate measures of cerebral blood flow, blood volume and oxygen consumption,” said Prof. Fantini. “This technique can be used not only to assess brain diseases but also to study the blood flow and how it is regulated in the healthy brain.”

Tufts University has licensed CHS on a non-exclusive basis to ISS (Champaign, IL, USA), a company that specializes in technology to measure hemoglobin concentration and oxygenation in brain and muscle tissue. “Potentially the market for CHS is large as it encompasses several applications from the monitoring of cerebrovascular disorders to assessing neurological disorders,” stated Beniamino Barbieri, president of ISS. “It reminds me of the introduction of ultrasound technology at beginning of the seventies; nobody back then knew how to utilize the new technology and of course, nowadays, its applications are ubiquitous in any medical center.”

CHS uses laser diodes which emit NIR light that is delivered to the scalp by fiber optics. Light waves are absorbed by the blood vessels in the brain. Remaining light is reflected back to sensors, resulting in optical signals that oscillate with time as a result of the heartbeat, respiration, or other sources of variations in the blood pressure. By analyzing the light signals with algorithms developed for this purpose, Prof. Fantini’s model is able to evaluate blood flow and the way the brain regulates it, which is one marker for brain health.

CHS technology has been evaluated among patients undergoing hemodialysis at Tufts Medical Center. Earlier published research has reported a lower cerebral blood flow in dialysis patients compared with healthy patients. “Noninvasive ways to measure local changes in cerebral blood flow, particularly during periods of stress such as hemodialysis, surgeries, and in the setting of stroke, could have major implications for maintaining healthy brain function,” said Daniel Weiner, MD, a nephrologist at Tufts Medical Center (Tufts MC) and associate professor of medicine at Tufts University School of Medicine (TUSM), who is a member of the research team.

Josh Kornbluth, MD, a neurologist at Tufts MC, and associate professor of medicine at TUSM, is also working with Prof. Fantini to study CHS’s potential to evaluate the cerebrovascular state of patients who suffer traumatic brain injury or stroke. They hope to assess CHS further among neurologic critical care patients.

“Having data about local cerebral blood flow and whether it is properly regulated can allow us to more accurately develop individualized therapy and interventions instead of choosing a ‘one size fits all’ approach to traumatic brain injury, stroke, or subarachnoid hemorrhage,” Dr. Kornbluth concluded.

Related Links:

Tufts University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Silver Member
Mobile X-Ray Barrier
Lead Acrylic Mobile X-Ray Barriers
New
Color Doppler Ultrasound System
KC20
New
Digital Radiography Generator
meX+20BT lite

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.